Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRR-02
- Development stage
- Preclinical
- Lead developer
- Commissariat à l’Énergie Atomique et aux Énergies Alternatives
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
MRR-02 is a proprietary small recombinant protein with cytoprotective properties designed to target the proximal tubular cells of the nephron [3771]. Developed by researchers at Inserm, Sorbonne University, and collaborating French institutions, MRR-02 is specifically reabsorbed by the S1 and S2 segments of the proximal tubule following subcutaneous administration [3771]. Upon internalization, the protein localizes to intracellular compartments, including the cytosol, mitochondria, and nuclei, where it exerts its cytoprotective effects [3771]. It is being investigated for the treatment and prevention of ischemia-induced acute kidney injury (AKI) [3771].
Beyond the preview
Go deeper on MRR-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRR-02.